Advertisement
Australia markets close in 4 hours 37 minutes

  • ALL ORDS

    8,141.40
    +21.20 (+0.26%)
     

  • ASX 200

    7,870.90
    +19.20 (+0.24%)
     

  • AUD/USD

    0.6669
    -0.0001 (-0.02%)
     

  • OIL

    79.06
    -0.20 (-0.25%)
     

  • GOLD

    2,425.50
    -0.40 (-0.02%)
     

  • Bitcoin AUD

    105,169.34
    -1,247.04 (-1.17%)
     

  • CMC Crypto 200

    1,525.20
    +36.66 (+2.46%)
     

  • AUD/EUR

    0.6141
    +0.0002 (+0.03%)
     

  • AUD/NZD

    1.0931
    -0.0004 (-0.04%)
     

  • NZX 50

    11,746.92
    +70.93 (+0.61%)
     

  • NASDAQ

    18,713.80
    +39.61 (+0.21%)
     

  • FTSE

    8,416.45
    -7.75 (-0.09%)
     

  • Dow Jones

    39,872.99
    +66.22 (+0.17%)
     

  • DAX

    18,726.76
    -42.20 (-0.22%)
     

  • Hang Seng

    19,225.26
    +4.64 (+0.02%)
     

  • NIKKEI 225

    38,711.30
    -235.63 (-0.60%)
     

Incyte to Present at Upcoming Investor Conference

Business Wire
·1-min read

WILMINGTON, Del., May 02, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

ADVERTISEMENT

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502751076/en/

Contacts

Incyte Contacts:
Media
media@incyte.com

Investors
ir@incyte.com